Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 13,084 matching trials from the live ClinicalTrials.gov search.
Conditions
Colon Cancer, Obesity
Interventions
High Fiber Diet Featuring Legumes (HLD), Healthy American Diet
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Schizophrenia
Interventions
Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo, Paliperidone palmitate 100 mg eq.
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Anaheim, California • Cerritos, California • Escondido, California + 29 more
Conditions
Developmental Disability, Intellectual Disability, Autism Spectrum Disorder, Congenital Anomaly, Fragile X Syndrome, Facioscapulohumeral Muscular Dystrophy 1
Interventions
Standard of care genetic testing group
Other
Lead sponsor
Bionano Genomics
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Atlanta, Georgia • Augusta, Georgia • Iowa City, Iowa + 5 more
Completed No phase listed Observational

Cardiogenomics Registry

NCT00861575
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years to 99 Years
Enrollment
2,601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Dopamine on Diabetic Retinopathy

NCT02706977
Conditions
Diabetes
Interventions
Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing
Drug · Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide
Procedure · Biological · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
70
States / cities
Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more
Conditions
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Oral Azacitidine, Positron Emission Tomography, Prednisone, Questionnaire Administration, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
75 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
176
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 79 Years
Enrollment
2,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
138
States / cities
Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more
Conditions
HIV Infections, Lipodystrophy
Interventions
Placebo, Serostim® 4 mg, Serostim® 2 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 22 more
Conditions
Psoriasis
Interventions
BI 695501, Humira
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Santa Ana, California + 11 more
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
Conditions
Adenovirus Infections
Interventions
cidofovir, Brincidofovir
Drug
Lead sponsor
SymBio Pharmaceuticals
Industry
Eligibility
2 Months and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Duarte, California • Palo Alto, California + 25 more
Conditions
Multiple Myeloma
Interventions
Bortezomib and Tipifarnib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Duarte, California • Atlanta, Georgia
Conditions
Binge Eating Disorder
Interventions
Lisdexamfetamine dimesylate
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
84
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 77 more
Conditions
Atypical Hemolytic Uremic Syndrome (aHUS)
Interventions
Ravulizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Hollywood, Florida • Atlanta, Georgia • Detroit, Michigan + 3 more
Conditions
Relapsed Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions
Pembrolizumab, Lenalidomide
Biological · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York
Conditions
Advanced Cancer
Interventions
FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
19
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Completed Not applicable Interventional Results available

VIVO Clinical Study

NCT01970007
Conditions
Symptomatic Venous Outflow Obstruction in the Iliofemoral Vein
Interventions
Zilver Vena Venous Self-Expanding Stent
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
29
States / cities
Birmingham, Alabama • Glendale, Arizona • Littleton, Colorado + 24 more
Conditions
Antibiotic Stewardship
Interventions
Opt-Out Protocol
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Atlanta, Georgia • Fayetteville, Georgia • Newnan, Georgia + 6 more
Active, not recruiting Phase 1Phase 2 Interventional

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Conditions
Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rituximab, Temsirolimus
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
11
States / cities
Denver, Colorado • Atlanta, Georgia • Rochester, Minnesota + 7 more
Conditions
Femur Fracture
Interventions
Ultrasound-Guided Fascia Iliaca Compartment Nerve Block
Procedure
Lead sponsor
Zachary Binder
Other
Eligibility
4 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 6 more
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 5 more
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Interventions
Casdatifan, Cabozantinib, Placebo
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
46
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 40 more